Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer
作者： Christos S Karapetis , Timothy J Price
DOI: 10.2217/CRC.12.14
关键词:
摘要: SUMMARY Molecular markers that predict benefit associated with treatments for advanced colon cancer are now part of routine clinical practice. Monoclonal antibodies target the EGF receptor have been shown to lack efficacy in cancers KRAS gene mutations. The used exclusively patients wild-type cancer. Such may not respond receptor-targeted therapy at all. Those initially will eventually develop resistance and inevitably progress. We review mechanisms primary secondary monoclonal antibody suggest strategies overcome resistance.
futuremedicine.com 
sci-hub.se 参考文章(88)
Sarah Edkins, Sarah O'Meara, Adrian Parker, Claire Stevens, Marcelo Reis, Siân Jones, Chris Greenman, Helen Davies, Gillian Dalgliesh, Simon Forbes, Chris Hunter, Raffaella Smith, Philip Stephens, Peter Goldstraw, Andrew Nicholson, Tsun Leung Chan, Victor E Velculescu, Siu Tsan Yuen, Suet Yi Leung, Michael R Stratton, P Andrew Futreal, Recurrent KRAS Codon 146 Mutations in Human Colorectal Cancer Cancer Biology & Therapy. ,vol. 5, pp. 928- 932 ,(2006) , 10.4161/CBT.5.8.3251
S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz, PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology. ,vol. 28, pp. 3534- 3534 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.3534
Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F
J ARNOLETTI, D BUCHSBAUM, Z HUANG, A HAWKINS, M KHAZAELI, M KRAUS, S VICKERS, Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. Journal of Gastrointestinal Surgery. ,vol. 8, pp. 960- 970 ,(2004) , 10.1016/J.GASSUR.2004.09.021
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
S Bouali, A-S Chrétien, C Ramacci, M Rouyer, S Marchal, T Galenne, P Juin, P Becuwe, J-L Merlin, P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Therapy. ,vol. 16, pp. 498- 507 ,(2009) , 10.1038/CGT.2008.100
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, Lidia Corsini, Nicola Silvestris, Daniele Santini, Gaspare Gulotta, Viviana Bazan, Nicola Gebbia, Fabio Fulfaro, Antonio Russo, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treatment Reviews. ,vol. 36, ,(2010) , 10.1016/S0305-7372(10)70021-9
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478